Shopping Cart 0
Cart Subtotal
AED 0

Massachusetts General Hospital - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Massachusetts General Hospital (MGH) is a healthcare service provider which offers research, education and therapeutic care services. The hospital provides treatment and patient care services in the therapeutic areas of allergy and immunology; hematology, orthopaedics, neurology and neurosurgery, oncology, dermatology, gastroenterology, cardiology, infectious diseases, pulmonary, urology, among others. It also offers palliative care, pediatrics and pediatric surgery; pelvic floor disorders center, physical medicine and rehabilitation service; plastic and reconstructive surgery, primary care, primary care associates, psychiatry, pulmonary and critical care medicine, radiation oncology and radiology services, among others. MGH also provides research, education and training programs at different research centers include ALS multidisciplinary clinic, back bay healthcare center, beacon hill primary care, blood donor center, Blum center, primary care-revere, burns center, cancer center for cardiac surgery, cardiology and other services and others.MGH is headquartered in Boston, Massachusetts, the US.

Massachusetts General Hospital-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deal Details 16

Partnerships 16

BERG, Massachusetts General Hospital and Brigham and Women's Hospital Enter into Research Agreement 16

Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 17

BrainStorm Cell Therapeutics Enters into Agreement with Massachusetts General Hospital and California Pacific Medical Center 19

Trianni Enters into Agreement with Massachusetts General Hospital 20

Kamada Expands Partnership with Massachusetts General Hospital 21

Aptuit Enters into Agreement with Massachusetts General Hospital 22

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 23

Abpro Enters into Co-Development Agreement with Massachusetts General Hospital 24

Abpro Enters into Research Agreement with Massachusetts General Hospital 25

Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 26

Cynata Therapeutics Enters into Agreement with Massachusetts General Hospital 28

Sernova Enters into Research Agreement with Massachusetts General Hospital 29

MagnaChip Enters into Research Agreement with MGH and Pohang University for Magnetic Bio-Sensor 30

Aria Neurosciences Enters into Partnership with Massachusetts General Hospital 31

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 32

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 34

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 35

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 36

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 37

Licensing Agreements 38

Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 38

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 39

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 40

Columbia Labs Enters into Licensing Agreement for IVR Technology 42

Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 43

Biohaven Pharma Enters into Licensing Agreement with General Hospital 44

MultiVir Amends Licensing Agreement with Massachusetts General Hospital 45

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 46

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 47

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 48

NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 49

Massachusetts General Hospital-Key Competitors 50

Massachusetts General Hospital-Key Employees 51

Massachusetts General Hospital-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Joint Venture 52

Recent Developments 53

Legal and Regulatory 53

Apr 17, 2018: FDA Allows the First Use of Tracer-QC at Massachusetts General Hospital 53

Government and Public Interest 54

Oct 04, 2018: Massachusetts General Hospital receives USD 3 million to pilot regional disaster health response program 54

Sep 05, 2018: Alzheimer's-associated tau protein disrupts molecular transport within neurons 55

Aug 28, 2018: Mass. General team finds how NF-2 gene mutations make cells hyper-responsive to growth factor signaling 57

Aug 15, 2018: New genome analysis scores risk of serious common diseases 59

Aug 06, 2018: A targeted approach to treating glioma 60

Aug 01, 2018: Researchers discover new type of lung cell, critical insights for cystic fibrosis 61

Jul 23, 2018: Protease inhibitors may increase risk of cardiovascular death in people with HIV and heart failure 63

Jun 14, 2018: Milstein Medical Asian American Partnership Foundation Announces 2018 Fellowship and Project Awards 65

Jun 04, 2018: First-Ever Scientific Research Awards Funded by ALK Positive in Partnership with LUNGevity Foundation 68

May 18, 2018: MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas 69

May 17, 2018: Automated system significantly improves identification of patients at risk for ventilator-associated pneumonia 70

Apr 24, 2018: Imaging may allow safe tPA treatment of patients with unwitnessed strokes 72

Apr 24, 2018: A Leading Method in Human Genetics Studies May Need to Be Reconsidered, as Researchers Discover Significant Distortions 74

Apr 11, 2018: RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor therapy for breast cancer 75

Apr 11, 2018: Mass. General-led study may reveal how chronic stress in early life increases vulnerability to PTSD 76

Apr 04, 2018: Relaxation response therapy may reduce blood pressure by altering expression of a distinct set of genes 78

Apr 02, 2018: Disease-Causing Mobile Element Identified with SMRT Sequencing, Validated with CRISPR 79

Mar 14, 2018: Obesity may promote resistance to antiangiogenic therapy for breast cancer 80

Mar 08, 2018: Three Dana-Farber researchers awarded new grant to accelerate multiple myeloma research 82

Feb 14, 2018: Cardiac macrophages found to contribute to a currently untreatable type of heart failure 83

Dec 21, 2017: MGH team engineers anti-inflammatory antibodies that may treat autoimmune disease 85

Nov 15, 2017: Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions 86

Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 88

Oct 17, 2017: Early gene transcription patterns in virus-specific CD8 T cells differentiate chronic from resolving hepatitis C infection 90

Oct 10, 2017: Massachusetts General team creates functional, stem-cell-derived small bowel segments 93

Oct 03, 2017: Protein identified that drives initiation and growth of aggressive form of leukemia 95

Sep 20, 2017: Discovery helps improve accuracy of CRISPR-Cas9 gene editing 96

Aug 28, 2017: Medical treatment may prevent, alleviate mitral valve damage after a heart attack 98

Jul 26, 2017: Incorporating 12-step Program Elements Improves Substance-use Disorder Treatment in Adolescents 100

Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 102

Jul 14, 2017: Immunosuppression underlies resistance to anti-angiogenic therapy 105

May 31, 2017: Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy 107

May 31, 2017: Mass. General researchers show how Shigella survives passage through the gastrointestinal tract 109

May 24, 2017: Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment 111

May 10, 2017: Molecular imaging reveals mechanism for resistance to immune checkpoint blockade 112

Apr 25, 2017: Enzyme treatment reduces alcohol-induced liver damage in mouse models 113

Apr 20, 2017: Pretreatment HIV, immune activation levels determine their persistence during treatment 115

Feb 24, 2017: Molecular 'on switch' could point to treatments for pediatric brain tumor 117

Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 118

Jan 16, 2017: Protein identified by Mass General team may protect tumor-initiating breast cancer cells 120

Product News 121

Aug 06, 2018: Rapid diagnostic coupled with local therapy developed for brain tumors 121

06/21/2018: BCG vaccine leads to long-term improvement in blood sugar levels in type 1 diabetes patients 123

Jun 10, 2017: Mass. General study finds potential mechanism for BCG vaccine reversal of type 1 diabetes 124

06/10/2017: Mass. General study finds potential mechanism for BCG vaccine reversal of type 1 diabetes 125

May 31, 2017: Clinical trial investigates Alzheimer's disease drug in people with Down syndrome 126

May 07, 2018: Artificial intelligence detects patterns of gut microbes that indicate cholera risk 127

Apr 02, 2018: Combination immunotherapy improves survival in mouse models of mesothelioma 129

Mar 30, 2017: Single-cell RNA sequencing reveals detailed composition of two major types of brain tumor 131

Mar 19, 2018: Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort 132

Feb 27, 2018: Microfluidic device captures, allows analysis of tumor-specific extracellular vesicles 134

Jan 22, 2018: Combination chemotherapy may significantly improve treatment for deadly brain tumor 136

Other Significant Developments 138

Sep 04, 2018: IPRO-led panel reports consensus on anticoagulation management 138

Aug 13, 2018: Predicting risk for common deadly diseases from millions of genetic variants 139

Jul 04, 2018: Expanding primary care buprenorphine treatment could curb opioid overdose crisis 141

Jun 27, 2018: Patients believed to be allergic to penicillin have significantly increased risks of MRSA and C. difficile 143

Jun 01, 2018: Randomised Clinical Trial Shows That Sustained Counselling Yields Higher Tobacco Quit Rates 145

May 07, 2018: AI Detects Patterns of Gut Microbes for Cholera Risk 146

Oct 25, 2017: Mature B lymphocytes accelerate the healing of diabetic ulcers, other skin injuries 148

Appendix 150

Methodology 150

About GlobalData 150

Contact Us 150

Disclaimer 150


List Of Figure

List of Figures

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Key Facts 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

BERG, Massachusetts General Hospital and Brigham and Women's Hospital Enter into Research Agreement 16

Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 17

BrainStorm Cell Therapeutics Enters into Agreement with Massachusetts General Hospital and California Pacific Medical Center 19

Trianni Enters into Agreement with Massachusetts General Hospital 20

Kamada Expands Partnership with Massachusetts General Hospital 21

Aptuit Enters into Agreement with Massachusetts General Hospital 22

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 23

Abpro Enters into Co-Development Agreement with Massachusetts General Hospital 24

Abpro Enters into Research Agreement with Massachusetts General Hospital 25

Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 26

Cynata Therapeutics Enters into Agreement with Massachusetts General Hospital 28

Sernova Enters into Research Agreement with Massachusetts General Hospital 29

MagnaChip Enters into Research Agreement with MGH and Pohang University for Magnetic Bio-Sensor 30

Aria Neurosciences Enters into Partnership with Massachusetts General Hospital 31

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 32

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 34

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 35

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 36

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 37

Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 38

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 39

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 40

Columbia Labs Enters into Licensing Agreement for IVR Technology 42

Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 43

Biohaven Pharma Enters into Licensing Agreement with General Hospital 44

MultiVir Amends Licensing Agreement with Massachusetts General Hospital 45

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 46

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 47

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 48

NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 49

Massachusetts General Hospital, Key Competitors 50

Massachusetts General Hospital, Key Employees 51

Massachusetts General Hospital, Joint Venture 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Massachusetts General Hospital, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Massachusetts General Hospital (MGH) is a healthcare service provider which offers research, education and therapeutic care services. The hospital provides treatment and patient care services in the therapeutic areas of allergy and immunology; hematology, orthopaedics, neurology and neurosurgery, oncology, dermatology, gastroenterology, cardiology, infectious diseases, pulmonary, urology, among others. It also offers palliative care, pediatrics and pediatric surgery; pelvic floor disorders center, physical medicine and rehabilitation service; plastic and reconstructive surgery, primary care, primary care associates, psychiatry, pulmonary and critical care medicine, radiation oncology and radiology services, among others. MGH also provides research, education and training programs at different research centers include ALS multidisciplinary clinic, back bay healthcare center, beacon hill primary care, blood donor center, Blum center, primary care-revere, burns center, cancer center for cardiac surgery, cardiology and other services and others.MGH is headquartered in Boston, Massachusetts, the US.

Massachusetts General Hospital-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deal Details 16

Partnerships 16

BERG, Massachusetts General Hospital and Brigham and Women's Hospital Enter into Research Agreement 16

Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 17

BrainStorm Cell Therapeutics Enters into Agreement with Massachusetts General Hospital and California Pacific Medical Center 19

Trianni Enters into Agreement with Massachusetts General Hospital 20

Kamada Expands Partnership with Massachusetts General Hospital 21

Aptuit Enters into Agreement with Massachusetts General Hospital 22

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 23

Abpro Enters into Co-Development Agreement with Massachusetts General Hospital 24

Abpro Enters into Research Agreement with Massachusetts General Hospital 25

Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 26

Cynata Therapeutics Enters into Agreement with Massachusetts General Hospital 28

Sernova Enters into Research Agreement with Massachusetts General Hospital 29

MagnaChip Enters into Research Agreement with MGH and Pohang University for Magnetic Bio-Sensor 30

Aria Neurosciences Enters into Partnership with Massachusetts General Hospital 31

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 32

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 34

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 35

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 36

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 37

Licensing Agreements 38

Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 38

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 39

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 40

Columbia Labs Enters into Licensing Agreement for IVR Technology 42

Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 43

Biohaven Pharma Enters into Licensing Agreement with General Hospital 44

MultiVir Amends Licensing Agreement with Massachusetts General Hospital 45

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 46

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 47

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 48

NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 49

Massachusetts General Hospital-Key Competitors 50

Massachusetts General Hospital-Key Employees 51

Massachusetts General Hospital-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Joint Venture 52

Recent Developments 53

Legal and Regulatory 53

Apr 17, 2018: FDA Allows the First Use of Tracer-QC at Massachusetts General Hospital 53

Government and Public Interest 54

Oct 04, 2018: Massachusetts General Hospital receives USD 3 million to pilot regional disaster health response program 54

Sep 05, 2018: Alzheimer's-associated tau protein disrupts molecular transport within neurons 55

Aug 28, 2018: Mass. General team finds how NF-2 gene mutations make cells hyper-responsive to growth factor signaling 57

Aug 15, 2018: New genome analysis scores risk of serious common diseases 59

Aug 06, 2018: A targeted approach to treating glioma 60

Aug 01, 2018: Researchers discover new type of lung cell, critical insights for cystic fibrosis 61

Jul 23, 2018: Protease inhibitors may increase risk of cardiovascular death in people with HIV and heart failure 63

Jun 14, 2018: Milstein Medical Asian American Partnership Foundation Announces 2018 Fellowship and Project Awards 65

Jun 04, 2018: First-Ever Scientific Research Awards Funded by ALK Positive in Partnership with LUNGevity Foundation 68

May 18, 2018: MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas 69

May 17, 2018: Automated system significantly improves identification of patients at risk for ventilator-associated pneumonia 70

Apr 24, 2018: Imaging may allow safe tPA treatment of patients with unwitnessed strokes 72

Apr 24, 2018: A Leading Method in Human Genetics Studies May Need to Be Reconsidered, as Researchers Discover Significant Distortions 74

Apr 11, 2018: RB1 gene mutations underlie clinical resistance to CDK 4/6 inhibitor therapy for breast cancer 75

Apr 11, 2018: Mass. General-led study may reveal how chronic stress in early life increases vulnerability to PTSD 76

Apr 04, 2018: Relaxation response therapy may reduce blood pressure by altering expression of a distinct set of genes 78

Apr 02, 2018: Disease-Causing Mobile Element Identified with SMRT Sequencing, Validated with CRISPR 79

Mar 14, 2018: Obesity may promote resistance to antiangiogenic therapy for breast cancer 80

Mar 08, 2018: Three Dana-Farber researchers awarded new grant to accelerate multiple myeloma research 82

Feb 14, 2018: Cardiac macrophages found to contribute to a currently untreatable type of heart failure 83

Dec 21, 2017: MGH team engineers anti-inflammatory antibodies that may treat autoimmune disease 85

Nov 15, 2017: Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions 86

Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 88

Oct 17, 2017: Early gene transcription patterns in virus-specific CD8 T cells differentiate chronic from resolving hepatitis C infection 90

Oct 10, 2017: Massachusetts General team creates functional, stem-cell-derived small bowel segments 93

Oct 03, 2017: Protein identified that drives initiation and growth of aggressive form of leukemia 95

Sep 20, 2017: Discovery helps improve accuracy of CRISPR-Cas9 gene editing 96

Aug 28, 2017: Medical treatment may prevent, alleviate mitral valve damage after a heart attack 98

Jul 26, 2017: Incorporating 12-step Program Elements Improves Substance-use Disorder Treatment in Adolescents 100

Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 102

Jul 14, 2017: Immunosuppression underlies resistance to anti-angiogenic therapy 105

May 31, 2017: Radiation therapy, macrophages improve efficacy of nanoparticle-delivered cancer therapy 107

May 31, 2017: Mass. General researchers show how Shigella survives passage through the gastrointestinal tract 109

May 24, 2017: Brain microenvironment makes HER2-positive breast cancer metastases resistant to treatment 111

May 10, 2017: Molecular imaging reveals mechanism for resistance to immune checkpoint blockade 112

Apr 25, 2017: Enzyme treatment reduces alcohol-induced liver damage in mouse models 113

Apr 20, 2017: Pretreatment HIV, immune activation levels determine their persistence during treatment 115

Feb 24, 2017: Molecular 'on switch' could point to treatments for pediatric brain tumor 117

Feb 07, 2017: Cystinosis Research Foundation Grants Support Scientific Studies on Cell Function, New Treatments and the Quest for a Cure 118

Jan 16, 2017: Protein identified by Mass General team may protect tumor-initiating breast cancer cells 120

Product News 121

Aug 06, 2018: Rapid diagnostic coupled with local therapy developed for brain tumors 121

06/21/2018: BCG vaccine leads to long-term improvement in blood sugar levels in type 1 diabetes patients 123

Jun 10, 2017: Mass. General study finds potential mechanism for BCG vaccine reversal of type 1 diabetes 124

06/10/2017: Mass. General study finds potential mechanism for BCG vaccine reversal of type 1 diabetes 125

May 31, 2017: Clinical trial investigates Alzheimer's disease drug in people with Down syndrome 126

May 07, 2018: Artificial intelligence detects patterns of gut microbes that indicate cholera risk 127

Apr 02, 2018: Combination immunotherapy improves survival in mouse models of mesothelioma 129

Mar 30, 2017: Single-cell RNA sequencing reveals detailed composition of two major types of brain tumor 131

Mar 19, 2018: Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort 132

Feb 27, 2018: Microfluidic device captures, allows analysis of tumor-specific extracellular vesicles 134

Jan 22, 2018: Combination chemotherapy may significantly improve treatment for deadly brain tumor 136

Other Significant Developments 138

Sep 04, 2018: IPRO-led panel reports consensus on anticoagulation management 138

Aug 13, 2018: Predicting risk for common deadly diseases from millions of genetic variants 139

Jul 04, 2018: Expanding primary care buprenorphine treatment could curb opioid overdose crisis 141

Jun 27, 2018: Patients believed to be allergic to penicillin have significantly increased risks of MRSA and C. difficile 143

Jun 01, 2018: Randomised Clinical Trial Shows That Sustained Counselling Yields Higher Tobacco Quit Rates 145

May 07, 2018: AI Detects Patterns of Gut Microbes for Cholera Risk 146

Oct 25, 2017: Mature B lymphocytes accelerate the healing of diabetic ulcers, other skin injuries 148

Appendix 150

Methodology 150

About GlobalData 150

Contact Us 150

Disclaimer 150


List Of Figure

List of Figures

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Key Facts 2

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Massachusetts General Hospital, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Massachusetts General Hospital, Deals By Therapy Area, 2012 to YTD 2018 11

Massachusetts General Hospital, Medical Devices Deals, 2012 to YTD 2018 12

Massachusetts General Hospital, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

BERG, Massachusetts General Hospital and Brigham and Women's Hospital Enter into Research Agreement 16

Verge Genomics Enters into Agreement with Columbia University, Massachusetts General Hospital, University of Southern California, and University of Michigan 17

BrainStorm Cell Therapeutics Enters into Agreement with Massachusetts General Hospital and California Pacific Medical Center 19

Trianni Enters into Agreement with Massachusetts General Hospital 20

Kamada Expands Partnership with Massachusetts General Hospital 21

Aptuit Enters into Agreement with Massachusetts General Hospital 22

Seres Therapeutics Enters into Agreement with Massachusetts General Hospital 23

Abpro Enters into Co-Development Agreement with Massachusetts General Hospital 24

Abpro Enters into Research Agreement with Massachusetts General Hospital 25

Boehringer Ingelheim Enters into Research Agreement with Icahn School of Medicine, Massachusetts General Hospital, Scripps Research Institute and Weill Cornell Medicine 26

Cynata Therapeutics Enters into Agreement with Massachusetts General Hospital 28

Sernova Enters into Research Agreement with Massachusetts General Hospital 29

MagnaChip Enters into Research Agreement with MGH and Pohang University for Magnetic Bio-Sensor 30

Aria Neurosciences Enters into Partnership with Massachusetts General Hospital 31

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 32

Sanofi Enters Into R&D Agreement With Massachusetts General Hospital For Translational Oncology Research 34

Skinmedica Enters Into R&D Agreement With Massachusetts General Hospital 35

Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 36

ZELTIQ Aesthetics Enters Into Co-Development Agreement With Massachusetts General Hospital 37

Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 38

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 39

Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 40

Columbia Labs Enters into Licensing Agreement for IVR Technology 42

Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 43

Biohaven Pharma Enters into Licensing Agreement with General Hospital 44

MultiVir Amends Licensing Agreement with Massachusetts General Hospital 45

RetroSense Therapeutics to Enter into Licensing Agreement with Massachusetts General Hospital 46

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 47

Neon Therapeutics Enters into Licensing Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital 48

NanoString Technologies Enters Into Option For Licensing Agreement With Massachusetts General Hospital 49

Massachusetts General Hospital, Key Competitors 50

Massachusetts General Hospital, Key Employees 51

Massachusetts General Hospital, Joint Venture 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Massachusetts General Hospital, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.